Hyperparathyroidism

Higher Phosphate, PTH Predict Worse Outcomes

By

Hyperparathyroidism develops prior to significant hyperphosphatemia in patients with chronic kidney disease (CKD) but not on dialysis.

PTH Rise in CKD Greater in Blacks

By

Changes in calcium, phosphorus, and 25-hydroxyvitamin-D explain only part of this racial difference

Paricalcitol Superior for Lowering iPTH

By

The drug was more likely than cinacalcet to achieve a 50 percent or greater decrease in iPTH from baseline.

Antioxidant Nutraceutical May Help Treat Secondary Hyperparathyroidism

By

LAS VEGAS—A novel multivitamin antioxidant nutraceutical may be useful in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to data reported at the National Kidney Foundation's Spring Clinical Meetings.

Paricalcitol Use Lower Among Non-Diabetics On Statins

By

LAS VEGAS—Statin use by non-diabetic patients with end-stage renal disease may decrease paricalcitol use, researcher reported at the National Kidney Foundation's Spring Clinical Meetings.

Inpatient Savings May Offset Cinacalcet Costs

By

LAS VEGAS—Inpatient cost savings may offset the costs of patient adherence to cinacalcet therapy, according to study findings presented at the National Kidney Foundation's Spring Clinical Meetings.

25(OH)D Replacement Found Ineffective for SHPT

By

LAS VEGAS—Replacing 25-hydroxyvitamin D (25(OH)D) in hemodialysis (HD) patients who are deficient in the vitamin does not result in a significant decrease in intact parathyroid hormone (iPTH) level, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.

CKD Patients with Diabetes Experience Disordered Mineral Metabolism Sooner

By

LAS VEGAS—Disordered mineral metabolism starts earlier in the course of chronic kidney disease (CKD) and is more severe in patients with diabetes than in those without diabetes, investigators reported at the National Kidney Foundation's Spring Clinical Meetings.

Cinacalet Effective for Long-Term Management of Post-Tx Hyperparathyroidism

By

LAS VEGAS—Cinacalcet is effective for the long-term management of persistent hyperparathyroidism after renal transplantation, with deleterious impact on kidney function, researchers reported at the National Kidney Foundation's Spring Clinical Meeting.

Stone Make Up, Morphology May Indicate Hyperparathyroidism

By

Renal stones of certain compositions and morphological type may identify patients who should be screened for primary hyperparathyroidism (HPT), according to a new study.

Kidney Cysts, PHPT Linked

By

Patients with primary hyperparathyroidism (PHPT) have a high prevalence of simple kidney cysts, an Italian study found.